Similarly, the Checkmate 067 trial, which revolutionized the treatment landscape in metastatic melanoma, reported a doubling of the mOS in the anti-CTLA4/PD1 combination arm compared to the nivolumab arm at the 6.5-year trial update (72.1 vs. 36.9 months, respectively); however, this study was not powered to detect any differences between those two arms [27]. The gene discussed is CTLA4; the disease is metastatic melanoma.